drugset / Trial / NCT04617704
BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
Phase 0
Unknown
15 enrolled
Shanghai Changzheng Hospital
Gracell Biotechnologies (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open label, multi-center prospective study to explory the safety and efficacy of GC012F CAR-T cells in patient diagnosed with high-risk chromosomal abnormalities BCMA+ multiple myeloma(MM).
Timeline
- Start
- 2021-12-01
- Primary completion
- 2021-12-31
- Completion
- 2022-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | GC012F | Cell therapy | 500000 cells/kg | Intravenous |